ArticleScience translational medicine2018
Oncogenic JAK2
Abstract read
In one paragraph
Article in Science translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 163 papers.
0numbers the graph read from it
0cells of the map it votes in
163citing papers in PubMed
15.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
163 citing papers in PubMed, 221 citations in OpenAlex.
- Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.Nature communications · 2024Trial
- Platelets as non-canonical immune regulatory nodes: orchestrating T cell dysfunction and immunotherapy resistance in cancer.Apoptosis : an international journal on programmed cell death · 2026Review
- JAK2 Variant and Parkinsonian Syndromes: Coincidence or Pathophysiological Link?Movement disorders clinical practice · 2026Article
- Homozygosity of germ lineBlood neoplasia · 2026Article
- No evidence of immunosurveillance in mutation-hotspot-driven clonal hematopoiesis.Nature genetics · 2026Article
- Clonal Metamorphosis: Deconstructing MPN Evolution with Single-Cell and Spatial Multi-Omics.Clinical and experimental medicine · 2026Review
- Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2026Article
- Review
- Erythrocyte-anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial.Nature cancer · 2026Article
- Toward new therapy end points in polycythemia vera: targeting clonal and inflammatory pathways.Blood advances · 2026Review
- Allicin inhibits PD-L1 through the IL-6/JAK2/STAT3 pathway to suppress immune evasion in osteosarcoma.Frontiers in immunology · 2026Article
- STAT3 at the tumor-immune interface: mechanisms of immune escape and therapeutic opportunities.Frontiers in immunology · 2026Review
- Recombinant human adenovirus type 5 synergizes with anti-PD-L1 antibody to promote anti-hepatocellular carcinoma effects through multilevel remodeling of the immune microenvironment.Frontiers in immunology · 2026Article
- PD-L1 Expression in Acute Myeloid Leukemia Cells: Associations With Cell Metabolism.Journal of immunology research · 2026Article
- PD-1/PD-L1-CXCR3 Coexpression and CXCR3 on Intermediate Monocytes Predict Fibrosis, Leukemic Transformation, and Survival in Egyptian Philadelphia-Negative Myeloproliferative Neoplasms.Clinical Medicine Insights. Oncology · 2026Article
- Oncostatin M induced by STAT5-activating oncogenes promotes disease progression in hematologic malignancies.Signal transduction and targeted therapy · 2025Article
- Article
- Monocyte Involvement in the Pathogenesis of Myeloproliferative Neoplasms.International journal of molecular sciences · 2025Review
- Review
- Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling.Nature communications · 2025Article
103 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors at 9 institutions in 4 countries.
Alessandro PrestipinoDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.ORCID 0000-0001-8054-5008
Alica J EmhardtDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.ORCID 0000-0001-5828-2993
Konrad AumannInstitute of Surgical Pathology, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.ORCID 0000-0001-8178-1571
David O'SullivanMax Planck Institute for Immunobiology and Epigenetics, Freiburg 79108, Germany.
Sivahari P GorantlaDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.
Sandra DuquesneDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.
Wolfgang MelchingerDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.
Lukas BraunDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.ORCID 0000-0003-0770-4994
Slavica VuckovicDepartment of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia.ORCID 0000-0002-2803-0717
Melanie BoerriesInstitute of Molecular Medicine and Cell Research, Faculty of Medicine, University of Freiburg, Freiburg 79085, Germany.
Hauke BuschInstitute of Molecular Medicine and Cell Research, Faculty of Medicine, University of Freiburg, Freiburg 79085, Germany.ORCID 0000-0003-4763-4521
Sebastian HalbachInstitute of Molecular Medicine and Cell Research, Faculty of Medicine, University of Freiburg, Freiburg 79085, Germany.ORCID 0000-0002-6827-8178
Sandra PennisiDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.ORCID 0000-0003-4536-4775
Teresa PoggioDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.ORCID 0000-0003-2560-8488
Petya ApostolovaDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.
Pia VerattiDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.
Michael HettichDepartment of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.
Gabriele NiedermannDepartment of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.
Mark BartholomäDepartment of Nuclear Medicine, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.ORCID 0000-0002-0361-2833
Khalid ShoumariyehDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.ORCID 0000-0001-7969-1972
Jonas S JutziDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.ORCID 0000-0002-1977-153X
Julius WehrleDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.ORCID 0000-0001-6514-4230
Christine DierksDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.
Heiko BeckerDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.ORCID 0000-0002-6919-4048
Annette Schmitt-GraeffInstitute of Surgical Pathology, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.ORCID 0000-0001-5082-7979
Marie FolloDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.ORCID 0000-0002-3090-7442
Dietmar PfeiferDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.ORCID 0000-0003-2684-5944
Jan RohrCenter for Chronic Immunodeficiency, Medical Center, University of Freiburg, Freiburg 79106, Germany.ORCID 0000-0002-0390-406X
Sebastian FuchsCenter for Chronic Immunodeficiency, Medical Center, University of Freiburg, Freiburg 79106, Germany.ORCID 0000-0001-9191-7970
Stephan EhlCenter for Chronic Immunodeficiency, Medical Center, University of Freiburg, Freiburg 79106, Germany.
Frederike A HartlFaculty of Biology, Albert Ludwigs University of Freiburg, Freiburg 79104, Germany.
Susana MinguetFaculty of Biology, Albert Ludwigs University of Freiburg, Freiburg 79104, Germany.ORCID 0000-0001-8211-5538
Cornelius MiethingDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.ORCID 0000-0003-4699-3805
Florian H HeidelInternal Medicine II, Department of Hematology and Oncology, University Hospital of Jena, Jena 07745, Germany.ORCID 0000-0002-9559-7297
Nicolaus KrögerDepartment of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.ORCID 0000-0001-5103-9966
Ioanna TriviaiDepartment of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.ORCID 0000-0002-4420-4692
Tilman BrummerInstitute of Molecular Medicine and Cell Research, Faculty of Medicine, University of Freiburg, Freiburg 79085, Germany.ORCID 0000-0003-4387-7905
Jürgen FinkeDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.
Anna L IllertDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.
Eliana RuggieroUnit of Experimental Hematology, San Raffaele Scientific Institute, and University of Vita-Salute San Raffaele, Milano 20132, Italy.
Chiara BoniniUnit of Experimental Hematology, San Raffaele Scientific Institute, and University of Vita-Salute San Raffaele, Milano 20132, Italy.ORCID 0000-0002-0772-1674
Justus DuysterDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.
Heike L PahlDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.ORCID 0000-0003-2857-2396
Steven W LaneDepartment of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia.ORCID 0000-0002-8050-6209
Geoffrey R HillDepartment of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia.
Bruce R BlazarDivision of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-9608-9841
Nikolas von BubnoffDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.ORCID 0000-0001-9593-8947
Erika L PearceMax Planck Institute for Immunobiology and Epigenetics, Freiburg 79108, Germany.ORCID 0000-0001-5592-5439
Robert ZeiserDepartment of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany. robert.zeiser@uniklinik-freiburg.de.ORCID 0000-0001-6565-3393
University of Freiburg · DEUniversity Medical Center Freiburg · DEGerman Cancer Research Center · DEThe University of Queensland · AUMax Planck Institute of Immunobiology and Epigenetics · DEUniversität Hamburg · DEVita-Salute San Raffaele University · ITLeibniz Institute on Aging - Fritz Lipmann Institute (FLI) · DEUniversity of Minnesota · US
Funding
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2MTransgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SHARPE, ARLENE H. · 2003 to 2023
$42.5MEnhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7MGVL TO REDUCE AML RELAPSE AFTER MURINE ALLOGENEIC BMTR01CA072669 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1997 to 2017
$4.9MEuropean Research Council 681012NCI NIH HHS P01 CA065493NCI NIH HHS R01 CA072669NHLBI NIH HHS R01 HL118979NIAID NIH HHS P01 AI056299
Abstract
Recent evidence has revealed that oncogenic mutations may confer immune escape. A better understanding of how an oncogenic mutation affects immunosuppressive programmed death ligand 1 (PD-L1) expression may help in developing new therapeutic strategies. We show that oncogenic JAK2 (Janus kinase 2) activity caused STAT3 (signal transducer and activator of transcription 3) and STAT5 phosphorylation, which enhanced PD-L1 promoter activity and PD-L1 protein expression in JAK2
Indexed as
AnimalsB7-H1 AntigenCell ProliferationCell Transformation, NeoplasticHematologic NeoplasmsHumansJanus Kinase 2K562 CellsMiceMyeloproliferative DisordersSignal TransductionTumor Cells, CulturedB7-H1 AntigenJanus Kinase 2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.